Euthymics Bioscience

Neurovance receives patent for EB-1020, initiates ADHD trial

Friday, February 22, 2013 01:59 PM

The United States Patent and Trademark Office (USPTO) has issued Neurovance, a Cambridge, Mass.-based company spun out of Euthymics Bioscience, a notice of allowance for a composition of matter patent for EB-1020, providing proprietary protection for EB-1020 through July 2026.

More... »


Neurovance closes $7M series A1 round for ADHD drug

Friday, October 19, 2012 12:09 PM

Neurovance, has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020 for adult attention deficit hyperactivity disorder (ADHD).

More... »



CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs